LT3250575T - N-[3-[(4ar,7as)-2-amino-6-(5-fluorpirimidin-2-il)-4,4a,5,7-tetrahidropirolo[3,4-d][1,3]tiazin-7a-il]-4-fluor-fenil]-5-metoksi-pirazin-2-karboksamido tozilato druska - Google Patents

N-[3-[(4ar,7as)-2-amino-6-(5-fluorpirimidin-2-il)-4,4a,5,7-tetrahidropirolo[3,4-d][1,3]tiazin-7a-il]-4-fluor-fenil]-5-metoksi-pirazin-2-karboksamido tozilato druska

Info

Publication number
LT3250575T
LT3250575T LTEP16702654.1T LT16702654T LT3250575T LT 3250575 T LT3250575 T LT 3250575T LT 16702654 T LT16702654 T LT 16702654T LT 3250575 T LT3250575 T LT 3250575T
Authority
LT
Lithuania
Prior art keywords
tetrahydropyrrolo
fluoropyrimidin
thiazin
pyrazine
carboxamide
Prior art date
Application number
LTEP16702654.1T
Other languages
English (en)
Inventor
David Andrew Coates
Craig Daniel WOLFANGEL
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of LT3250575T publication Critical patent/LT3250575T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEP16702654.1T 2015-01-30 2016-01-22 N-[3-[(4ar,7as)-2-amino-6-(5-fluorpirimidin-2-il)-4,4a,5,7-tetrahidropirolo[3,4-d][1,3]tiazin-7a-il]-4-fluor-fenil]-5-metoksi-pirazin-2-karboksamido tozilato druska LT3250575T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562109733P 2015-01-30 2015-01-30
PCT/US2016/014423 WO2016122968A1 (en) 2015-01-30 2016-01-22 Tosylate salt of n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide

Publications (1)

Publication Number Publication Date
LT3250575T true LT3250575T (lt) 2020-02-10

Family

ID=55275232

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16702654.1T LT3250575T (lt) 2015-01-30 2016-01-22 N-[3-[(4ar,7as)-2-amino-6-(5-fluorpirimidin-2-il)-4,4a,5,7-tetrahidropirolo[3,4-d][1,3]tiazin-7a-il]-4-fluor-fenil]-5-metoksi-pirazin-2-karboksamido tozilato druska

Country Status (41)

Country Link
US (1) US10080758B2 (lt)
EP (1) EP3250575B1 (lt)
JP (2) JP6723250B2 (lt)
KR (1) KR101950129B1 (lt)
CN (1) CN107108657B (lt)
AR (1) AR103406A1 (lt)
AU (1) AU2016211827B2 (lt)
BR (1) BR112017012149A2 (lt)
CA (1) CA2969475C (lt)
CL (1) CL2017001899A1 (lt)
CO (1) CO2017007810A2 (lt)
CR (1) CR20170287A (lt)
CY (1) CY1122548T1 (lt)
DK (1) DK3250575T3 (lt)
DO (1) DOP2017000159A (lt)
EA (1) EA031330B1 (lt)
EC (1) ECSP17048768A (lt)
ES (1) ES2768782T3 (lt)
GT (1) GT201700166A (lt)
HR (1) HRP20192240T1 (lt)
HU (1) HUE048029T2 (lt)
IL (1) IL252754A0 (lt)
LT (1) LT3250575T (lt)
MA (1) MA41420B1 (lt)
MD (1) MD3250575T2 (lt)
ME (1) ME03581B (lt)
MX (1) MX2017009713A (lt)
NZ (1) NZ732381A (lt)
PE (1) PE20171333A1 (lt)
PH (1) PH12017501356A1 (lt)
PL (1) PL3250575T3 (lt)
PT (1) PT3250575T (lt)
RS (1) RS59730B1 (lt)
SG (1) SG11201706038PA (lt)
SI (1) SI3250575T1 (lt)
SV (1) SV2017005478A (lt)
TN (1) TN2017000332A1 (lt)
TW (1) TWI574969B (lt)
UA (1) UA119581C2 (lt)
WO (1) WO2016122968A1 (lt)
ZA (1) ZA201703937B (lt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103406A1 (es) * 2015-01-30 2017-05-10 Lilly Co Eli Sal de tosilato
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT401651B (de) * 1994-06-14 1996-11-25 Biochemie Gmbh 7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4-
NZ585671A (en) * 2007-12-07 2012-06-29 Pfizer Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-fluoro-4- (pyrrolidin-1-yl-methyl) -phenyl] cyclobut anecarboxamide
US8158620B2 (en) * 2008-01-18 2012-04-17 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives
TWI593692B (zh) * 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
TWI570127B (zh) * 2014-09-15 2017-02-11 美國禮來大藥廠 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
AR103406A1 (es) * 2015-01-30 2017-05-10 Lilly Co Eli Sal de tosilato

Also Published As

Publication number Publication date
RS59730B1 (sr) 2020-02-28
MX2017009713A (es) 2017-11-17
DK3250575T3 (da) 2020-01-20
US20170368071A1 (en) 2017-12-28
EP3250575B1 (en) 2019-11-20
ZA201703937B (en) 2019-01-30
CL2017001899A1 (es) 2018-03-23
JP2019142902A (ja) 2019-08-29
SG11201706038PA (en) 2017-08-30
SI3250575T1 (sl) 2019-12-31
EP3250575A1 (en) 2017-12-06
ECSP17048768A (es) 2017-11-30
CA2969475C (en) 2019-06-18
GT201700166A (es) 2018-11-23
SV2017005478A (es) 2018-02-09
HUE048029T2 (hu) 2020-05-28
TN2017000332A1 (en) 2019-01-16
ES2768782T3 (es) 2020-06-23
IL252754A0 (en) 2017-08-31
PH12017501356A1 (en) 2017-12-11
KR20170097782A (ko) 2017-08-28
EA031330B1 (ru) 2018-12-28
CA2969475A1 (en) 2016-08-04
PE20171333A1 (es) 2017-09-13
MA41420B1 (fr) 2020-02-28
BR112017012149A2 (pt) 2018-01-02
KR101950129B1 (ko) 2019-02-19
HRP20192240T1 (hr) 2020-03-06
ME03581B (me) 2020-07-20
JP6723250B2 (ja) 2020-07-15
AR103406A1 (es) 2017-05-10
CN107108657A (zh) 2017-08-29
NZ732381A (en) 2018-05-25
EA201791229A1 (ru) 2017-11-30
CN107108657B (zh) 2021-10-08
US10080758B2 (en) 2018-09-25
CO2017007810A2 (es) 2017-10-20
DOP2017000159A (es) 2017-07-31
PT3250575T (pt) 2020-01-16
JP2018503666A (ja) 2018-02-08
AU2016211827A1 (en) 2017-06-22
TWI574969B (zh) 2017-03-21
CY1122548T1 (el) 2021-01-27
WO2016122968A1 (en) 2016-08-04
TW201636354A (zh) 2016-10-16
MD3250575T2 (ro) 2020-03-31
PL3250575T3 (pl) 2020-06-01
AU2016211827B2 (en) 2018-04-26
UA119581C2 (uk) 2019-07-10
CR20170287A (es) 2017-07-20

Similar Documents

Publication Publication Date Title
IL264092A (en) 1, 3-dihydroxy-phenyl derivatives are useful as immunomodulators
IL260011B (en) History of water-soluble 5,3-diphenyldiazole compounds
ZA201900505B (en) Processes for the preparation of 4-alkoxy-3-(acyl or alkyl)oxypicolinamides
DK3397621T3 (da) Fremgangsmåde til fremstilling af 1,1,3-trioxo-1,2-benzothiazol-6-carboxamid
IL275126B (en) Methods for predicting the progression of Barrett's esophagus
HK1256825A1 (zh) 取代的5，6-二氫-6-苯基苯並[f]異喹啉-2-胺化合物的固體形式
ZA201703937B (en) Tosylate salt of n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide
ZA201708769B (en) Separation of enantiomers of 3-ethylbicyclo[3.2.0]hept-3-en-6-one
DK3397620T3 (da) Fremgangsmåde til fremstilling af 1,1,3-Trioxo-1,2-benzothiazol-6-carboxamid
GB2561089B (en) Process for the preparation of 17beta-hydroxy-des-a-androst-9, 10-en-5-one
HK1245267A1 (zh) 用於製備噻吩並-吲哚衍生物的不對稱方法
PT3102565T (pt) Processos para a preparação de intermediários de raltegravir
HUP1500451A2 (en) Processes for the preparation of 1,4,7-triaza-cyclononane derivatives and intermediates
TH182870B (th) เกลือทอซิเลทของ n-[3-[(4ar,7as)-2-อะมิโน-6-(5-ฟลูออโรพิริมิดิน-2-อิล)-4,4a,5,7-เททระไฮโดรพิร์โรโล[3,4-d][1,3]ไธอะซิน-7a-อิล]-4-ฟลูออโร-เฟนิล]-5-เมธอกซิ-ไพแรซีน-2-คาร์บอกแซมีด
GB2533003B (en) An over-garment comprising means for detachably affixing the over-garment to the waistband or belt of an item of apparel located inside it.
GB201512065D0 (en) Platin pleasure